500 million yuan! Five subsidiaries of this pharmaceutical company

[pharmaceutical network enterprise news] recently, the actual controller of Laimei pharmaceutical entrusted the voting rights of 184 million shares it held to Zhongheng group, which will control 194 million shares of Laimei pharmaceutical, accounting for 23.94% of the total share capital of Laimei pharmaceutical This also means that Zhongheng group will become the controlling shareholder of Laimei pharmaceutical, and Guangxi SASAC, the actual controller of Zhongheng group, will become the actual controller of Laimei pharmaceutical On February 11, Laimei pharmaceutical announced that the company plans to dispose of the assets of its five subsidiaries on the grounds that some products of Zhongheng group are similar to those of Laimei pharmaceutical and its subsidiaries in terms of ingredients and indications, and there may be horizontal competition or potential horizontal competition By February 12, Laimei pharmaceutical had begun to centrally dispose of the assets of its five subsidiaries   According to the announcement, the five subsidiaries to be disposed by Laimei Pharmaceutical Co., Ltd include: 100% equity of Hunan Kangyuan Pharmaceutical Co., Ltd (hereinafter referred to as "Hunan Kangyuan"), 90% equity of Chengdu Jinxing Health Pharmaceutical Co., Ltd (hereinafter referred to as "Chengdu Jinxing"), 100% equity of Sichuan Hezheng Pharmaceutical Co., Ltd (hereinafter referred to as "Sichuan Hezheng") (including its wholly-owned subsidiary Chengdu Hezheng Biological Technology Co., Ltd Technology Co., Ltd (hereinafter referred to as "Chengdu Hezheng"), Sichuan Laihe Pharmaceutical Technology Co., Ltd (hereinafter referred to as "Laihe technology"), Chongqing Laimei Health Industry Co., Ltd (hereinafter referred to as "Laimei health") 60% equity and Chongqing Laimei rat Herbal Pieces Co., Ltd (hereinafter referred to as "Laimei rat") 70% equity For the specific reasons for disposing the assets of five subsidiaries, Laimei pharmaceutical mentioned two reasons in the announcement On the one hand, in recent years, with the frequent emergence of various industrial policies such as "4 + 7" volume procurement, payment by disease, and restrictions on auxiliary drugs, the competition in the pharmaceutical industry has intensified The company should focus on the existing advantages and segments, and further refine and strengthen On the other hand, in view of the core business of Zhongheng group is Chinese patent medicine manufacturing, in order to avoid horizontal competition between Zhongheng group and the company and its subsidiaries, the equity of subsidiaries is disposed According to the data, the core product of Heng Group is traditional Chinese medicine injection, which intends to expand its layout in the field of biomedicine After Zhongheng group obtains the control right of the company, the group takes the company as a platform for the development, production and sales of innovative biomedical technology and products in its system, so as to enhance the position of Zhongheng group in the biomedical industry It is worth noting that according to the announcement of Laimei pharmaceutical's reply to the inquiry letter of Shenzhen Stock Exchange recently, four of the five subsidiaries to be disposed by Laimei pharmaceutical are all in deficit, of which Chengdu Jinxing lost 31.15 million yuan Only Sichuan Hezheng is profitable, with a net profit of 5.01 million yuan in 2019 The 2019 semi annual report of Laimei pharmaceutical also shows that there is a goodwill impairment provision of 19.0176 million yuan in Kangyuan, Hunan Province In addition, according to the 2019 annual performance forecast report released by Laimei pharmaceutical on January 23, the estimated value of asset groups of these five subsidiaries is about 520 million yuan, while the company expects to withdraw about 130 million yuan of related asset impairment loss in 2019 Laimei pharmaceutical industry's performance forecast in 2019 shows that its annual expected loss is 175 million yuan – 180 million yuan, a decrease of 278.57% - 283.67% over the same period of last year, and the profit of Laimei pharmaceutical industry in 2018 is 98.0033 million yuan According to the data, Laimei Pharmaceutical Co., Ltd was founded in 1999 and is a pharmaceutical manufacturer with complete injection forms in China In October 2009, the company was listed on the gem of Shenzhen Stock Exchange The total assets of the company is 2.74 billion yuan.